Genome & Company (KOSDAQ:314130)
2,965.00
-185.00 (-5.87%)
At close: Nov 16, 2026
| Market Cap | 155.07B +64.9% |
| Revenue (ttm) | 24.46B +1.8% |
| Net Income | -41.36B |
| EPS | -1,180.23 |
| Shares Out | 52.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 540,405 |
| Open | 3,180.00 |
| Previous Close | 3,150.00 |
| Day's Range | 2,870.00 - 3,275.00 |
| 52-Week Range | 2,745.00 - 10,180.00 |
| Beta | 0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |